Stockreport

Catalyst Biosciences Presents Positive Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) and Marzeptacog alfa (activated) (MarzAA) Programs at the 13th Annual EAHAD Co...

Catalyst Biosciences, Inc.  (CBIO) 
Last catalyst biosciences, inc. earnings: 11/7 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: catalystbiosciences.com/investors
PDF Enrollment in the DalcA trial is complete; results demonstrate DalcA provides Factor IX (FIX) activity exceeding the efficacy endpoint with no anti-drug antibodies Comp [Read more]